Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2026)

Aurinia Pharmaceuticals has reported Change in Accured Expenses for 7 years, with the latest figure at -$5.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 76.11% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.2 million (up 715.15% YoY), and the FY2025 full-year result was -$4.7 million, down 134.92% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.6 million, down from $13.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $17.5 million in Q4 2024, with the low at -$23.4 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged $984000.0 across 5 years, with a median of $462000.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 5931.36% — and 2025, when it sank 194.92%.
• Aurinia Pharmaceuticals' Change in Accured Expenses stood at $616000.0 in 2022, then slumped by 44.48% to $342000.0 in 2023, then jumped by 5007.89% to $17.5 million in 2024, then fell by 24.88% to $13.1 million in 2025, then plunged by 142.62% to -$5.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$5.6 million (Q1 2026), $13.1 million (Q4 2025), and -$641000.0 (Q3 2025), per Business Quant data.